Fortress Biotech Stock Price, News & Analysis (NASDAQ:FBIO)

$3.44 -0.08 (-2.27 %)
(As of 12/17/2017 07:00 AM ET)
Previous Close$3.44
Today's Range$3.40 - $3.51
52-Week Range$1.88 - $5.13
Volume178,230 shs
Average Volume81,475 shs
Market Capitalization$174.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Debt-to-Equity Ratio0.42%
Current Ratio2.69%
Quick Ratio2.69%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.48 million
Price / Sales10.57
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book2.02

Profitability

Trailing EPS($1.83)
Net Income$-55,090,000.00
Net Margins-65.80%
Return on Equity-61.43%
Return on Assets-33.68%

Miscellaneous

Employees45
Outstanding Shares50,660,000

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech Inc (NASDAQ:FBIO) issued its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.24. The biopharmaceutical company had revenue of $46.89 million for the quarter, compared to analysts' expectations of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The firm's revenue for the quarter was up 4709.2% compared to the same quarter last year. View Fortress Biotech's Earnings History.

When will Fortress Biotech make its next earnings announcement?

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Fortress Biotech.

Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?

4 Wall Street analysts have issued 1 year target prices for Fortress Biotech's shares. Their predictions range from $11.00 to $11.00. On average, they expect Fortress Biotech's stock price to reach $11.00 in the next twelve months. View Analyst Ratings for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:

  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (10/10/2017)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:

  • Lindsay A. Rosenwald M.D., Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Eric K. Rowinsky M.D., Vice Chairman of the Board (Age 60)
  • Robyn Hunter, Chief Financial Officer (Age 55)
  • Michael S. Weiss, Executive Vice Chairman - Strategic Development (Age 51)
  • Lucy Lu M.D., Executive Vice President (Age 40)
  • George C. Avgerinos Ph.D., Senior Vice President - Biologics Operations (Age 62)
  • Malcolm I. Hoenlein, Director (Age 73)
  • David J. Barrett CPA, , Independent Director (Age 39)
  • Jimmie Harvey Jr., M.D., Independent Director (Age 63)
  • J. Jay Lobell J.D., Independent Director (Age 52)

Who owns Fortress Biotech stock?

Fortress Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include Strs Ohio (0.27%), Wells Fargo & Company MN (0.24%) and Citadel Advisors LLC (0.05%). Company insiders that own Fortress Biotech stock include George Avgerinos and Lindsay A Md Rosenwald. View Institutional Ownership Trends for Fortress Biotech.

Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?

Fortress Biotech's stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Wells Fargo & Company MN and Citadel Advisors LLC. View Insider Buying and Selling for Fortress Biotech.

How do I buy Fortress Biotech stock?

Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of Fortress Biotech stock can currently be purchased for approximately $3.44.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $174.26 million and generates $16.48 million in revenue each year. The biopharmaceutical company earns $-55,090,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Fortress Biotech employs 45 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Fortress Biotech (FBIO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fortress Biotech (NASDAQ:FBIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.60$10.60$10.60$10.33
Price Target Upside: 190.41% upside161.73% upside161.73% upside172.65% upside

Fortress Biotech (NASDAQ:FBIO) Consensus Price Target History

Price Target History for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ:FBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$11.00LowView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Fortress Biotech (NASDAQ:FBIO) Earnings History and Estimates Chart

Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ FBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.63)N/AView Earnings Details
11/9/2017Q3 2017($0.43)($0.67)$50.75 million$46.89 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Fortress Biotech (NASDAQ:FBIO) Earnings Estimates

2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fortress Biotech (NASDAQ:FBIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Fortress Biotech (NASDAQ FBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 12.05%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ FBIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2017George AvgerinosSVPSell25,593$3.59$91,878.87View SEC Filing  
11/6/2017Lindsay A Md RosenwaldCEOBuy40,000$25.00$1,000,000.00View SEC Filing  
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fortress Biotech (NASDAQ FBIO) News Headlines

Source:
DateHeadline
Fortress Biotech Inc (FBIO) SVP George Avgerinos Sells 25,593 SharesFortress Biotech Inc (FBIO) SVP George Avgerinos Sells 25,593 Shares
www.americanbankingnews.com - December 14 at 9:20 PM
Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - GlobeNewswire (press release)Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:25 PM
Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
finance.yahoo.com - December 14 at 10:08 AM
Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
finance.yahoo.com - December 14 at 10:08 AM
Fortress Biotech (FBIO) Given Buy Rating at HC WainwrightFortress Biotech (FBIO) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - December 12 at 8:52 AM
Mustang Bios MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid LeukemiaMustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia
www.nasdaq.com - December 11 at 5:03 PM
Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual MeetingFortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting
finance.yahoo.com - December 11 at 5:03 PM
Mustang Bios MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical TrialMustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
finance.yahoo.com - December 11 at 5:03 PM
Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL AmyloidosisCaelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis
finance.yahoo.com - December 11 at 10:42 AM
Checkpoint Therapeutics Wins A New Bull As Companys Plan Is Quickly Coming TogetherCheckpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'
finance.yahoo.com - December 8 at 4:49 PM
Fortress Biotech Inc (FBIO) Given Consensus Rating of "Buy" by BrokeragesFortress Biotech Inc (FBIO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 8 at 8:06 AM
Big apple-based biotech’s new gene therapy subsidiary inks UNC licensing dealsBig apple-based biotech’s new gene therapy subsidiary inks UNC licensing deals
finance.yahoo.com - December 5 at 4:51 PM
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet ... - GlobeNewswire (press release)Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 10:43 AM
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical NeedsFortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical Needs
finance.yahoo.com - December 5 at 10:43 AM
HC Wainwright Reiterates $11.00 Price Target for Fortress Biotech (FBIO)HC Wainwright Reiterates $11.00 Price Target for Fortress Biotech (FBIO)
www.americanbankingnews.com - December 5 at 10:34 AM
Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel ... - GlobeNewswire (press release)Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel ... - GlobeNewswire (press release)
globenewswire.com - December 4 at 9:59 AM
Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T TherapiesMustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
finance.yahoo.com - December 4 at 9:59 AM
Fortress Biotech (FBIO) Cut to Sell at ValuEngineFortress Biotech (FBIO) Cut to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 3:12 PM
Fortress Biotech: Revenue Growth, Analyst Target and Near Term CatalystsFortress Biotech: Revenue Growth, Analyst Target and Near Term Catalysts
finance.yahoo.com - November 30 at 10:28 AM
Fortress Biotech (FBIO) versus Kamada (KMDA) Critical ContrastFortress Biotech (FBIO) versus Kamada (KMDA) Critical Contrast
www.americanbankingnews.com - November 26 at 1:30 PM
Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate HighlightsMustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 14 at 6:59 PM
Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate ControllerMustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller
finance.yahoo.com - November 14 at 6:59 PM
Fortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from BrokeragesFortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - November 11 at 8:44 AM
Fortress Biotech, Inc. (FBIO) Posts  Earnings Results, Misses Expectations By $0.24 EPSFortress Biotech, Inc. (FBIO) Posts Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Fortress Biotech reports 3Q lossFortress Biotech reports 3Q loss
finance.yahoo.com - November 10 at 2:45 PM
Fortress Biotech (FBIO) Announces Cellvations CEVA101 Granted ... - StreetInsider.comFortress Biotech (FBIO) Announces Cellvation's CEVA101 Granted ... - StreetInsider.com
www.streetinsider.com - November 9 at 2:58 AM
Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain InjuryFortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury
finance.yahoo.com - November 9 at 2:58 AM
Insider Buying: Fortress Biotech, Inc. (FBIO) CEO Buys 40,000 Shares of StockInsider Buying: Fortress Biotech, Inc. (FBIO) CEO Buys 40,000 Shares of Stock
www.americanbankingnews.com - November 8 at 6:50 PM
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - GlobeNewswire (press release)Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - GlobeNewswire (press release)
globenewswire.com - November 8 at 6:51 AM
Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)
globenewswire.com - November 2 at 5:44 AM
Mustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ Breast Cancer Metastasis to BrainMustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ Breast Cancer Metastasis to Brain
www.streetinsider.com - November 1 at 7:40 PM
Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual MeetingMustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 7:40 PM
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual MeetingCaelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 7:40 PM
Data support clinical development of MB-103 HER2 CAR T cell therapyData support clinical development of MB-103 HER2 CAR T cell therapy
globenewswire.com - October 31 at 7:46 PM
Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the BrainMustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
finance.yahoo.com - October 31 at 7:46 PM
Fortress Biotech, Inc. (FBIO) Scheduled to Post Quarterly Earnings on TuesdayFortress Biotech, Inc. (FBIO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:34 AM
ETFs with exposure to Fortress Biotech, Inc. : October 30, 2017ETFs with exposure to Fortress Biotech, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 7:24 PM
Fortress Biotech Is Now Oversold (FBIO)Fortress Biotech Is Now Oversold (FBIO)
www.thestreet.com - October 20 at 5:05 PM
ETFs with exposure to Fortress Biotech, Inc. : October 20, 2017ETFs with exposure to Fortress Biotech, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 5:05 PM
Fortress Biotech, Inc. (FBIO) Given Consensus Rating of "Buy" by BrokeragesFortress Biotech, Inc. (FBIO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 10:46 AM
Fortress Biotech, Inc. (FBIO) Short Interest Down 55.2% in SeptemberFortress Biotech, Inc. (FBIO) Short Interest Down 55.2% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of ... - GlobeNewswire (press release)Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 7:27 PM
Mustang research partner City of Hope awarded California Institute for Regenerative Medicine grant to support ongoing Phase 1 studyMustang research partner City of Hope awarded California Institute for Regenerative Medicine grant to support ongoing Phase 1 study
www.nasdaq.com - October 11 at 8:06 PM
Fortress Biotech Stock Sees Short Interest Move 55.2% LowerFortress Biotech Stock Sees Short Interest Move 55.2% Lower
www.thestreet.com - October 11 at 8:06 PM
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant GliomaMustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
finance.yahoo.com - October 11 at 8:06 PM
ETFs with exposure to Fortress Biotech, Inc. : October 9, 2017ETFs with exposure to Fortress Biotech, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 6:50 PM
Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 6:59 PM
Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 - GlobeNewswire (press release)Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 - GlobeNewswire (press release)
globenewswire.com - October 5 at 9:13 AM
Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301
finance.yahoo.com - October 5 at 9:13 AM

SEC Filings

Fortress Biotech (NASDAQ:FBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fortress Biotech (NASDAQ:FBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fortress Biotech (NASDAQ FBIO) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.